The frequency of KRAS mutations in patients with highly aggressive cancers such as pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non–small cell lung carcinoma (NSCLC) is very high representing 90%, 35%, and 30% of all cases, respectively. This evidence concerns the gene KRAS and non-small cell lung carcinoma.